Abstract:HepatoBiliary Surg Nutr 2021 | https://dx.doi.org/10.21037/hbsn-21-365 Colorectal liver metastases (CRLM) are one of the most frequent clinical conditions. Over the last 20 years, the clinical outcome for patients with CRLM has improved greatly. Liver resection is the gold standard treatment for resectable CRLM, achieving a 5-year overall survival (OS) rate of 42% (1). However, the majority of patients with CRLM are not candidates for resection. With the development of thermal ablation, this technique provides an alternative treatment modality by either ablation alone or combined with resection. A recent review by Takahashi et al. summarized the current role of thermal ablation in the management of CRLM (2). In this review, the authors stated that ablation should not be used in lieu of liver resection for resectable CRLM based on current available evidence. Regarding the rapid advancement of systemic and local therapy, the treatment strategies for patients with CRLM are suggested to be discussed by the multidisciplinary team (MDT). Also, the authors listed the indications of ablation in their center, including unresectable liver lesions (tumor number ≤8, tumor size ≤4 cm), combined with hepatectomy, and resectable liver lesions but patients unfit to receive resection because of comorbidities and patient preference. These indications are highly feasible and can be referred by readers. It is noteworthy that the preferred tumor size and number were inconsistent in the light of the clinician’s experience. In general, thermal ablation is recommended for tumor size ≤3 cm. For tumor size between 3 and 5 cm, welllocated tumors can also be effectively treated depending on anatomical position and the treatment protocol used (3). Tumor number varies from 5 to 9 in the literature, which depends on the total liver tumor volume. The authors then pointed out the pros and cons of 3 approaches to perform ablation. Open and laparoscopy approaches allow better staging for occult liver metastases or peritoneal disease and protect surrounding organs from thermal injuries. It has been reported that additional metastases were detected in 10–25% of patients with CRLM by intraoperative ultrasound (4), which may result in changing the surgical strategy. The percutaneous approach provides the least invasive approach and has a significant role in patients with limited recurrent liver metastases after resection or ablation. Moreover, percutaneous ablation can be used as the ‘test-of-time’ approach reported by Livraghi et al. (5). The rationale of this approach is: (I) high technical success rate of ablation for small tumors without the need for resection; (II) if ablation was unsuccessful, the resection was still feasible; (III) if patients develop additional lesions after ablation and would no longer be suitable for resection, they can be spared unnecessary surgery. Among the 88 patients treated in the study by Livraghi et al. (5), 26% remained free of disease without the need for resection, 24% underwent resection after ablation, and 50% were unfit for resection due to disease progression. Compared with liver resection, local tumor recurrence (LTR) is a major issue after ablation. Predictors of LTR include tumor size ≥3 cm and ablation margin ≤0.5 cm. In Editorial

Achievement of textbook outcome after hepatectomy combined with thermal ablation for colorectal liver metastases

[Percutaneous Microwave/Radiofrequency Ablation Liver Partition and Portal Vein Embolization for Planned Hepatectomy for Colorectal Liver Metastases with Insufficient Future Liver Remnant].

Combined transarterial chemoembolization and thermal ablation in candidates to liver transplantation with hepatocellular carcinoma: pathological findings and post-transplant outcome

Oncologic Outcomes after Percutaneous Ablation for Colorectal Liver Metastases: An Updated Comprehensive Review

Short- and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for patients with multiple primarily unresectable colorectal liver metastases: a propensity matching analysis

Perioperative and Oncological Outcomes of Combined Hepatectomy with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer

Textbook Outcomes and Quality of Life Assessment Following Liver Resection for Colorectal Metastasis

Mid-term Outcome of Percutaneous Thermal Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma after Liver Transplantation.

Textbook outcomes in the liver-first approach for colorectal liver metastases: prospective multicentre analysis

Have we improved postoperative and long-term outcomes of liver surgery for colorectal cancer metastasis? Analysis of 1736 hepatectomies performed over 3 decades in a single center

Percutaneous Thermal Ablation for the Treatment of Colorectal Liver Metastases and Hepatocellular Carcinoma: a Comparison of Local Therapeutic Efficacy

Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma

Resection versus resection with ablation: Analysis from the colorectal liver operative metastasis international collaborative

Realizing Textbook Outcomes Following Liver Resection for Hepatic Neoplasms with Development and Validation of a Predictive Nomogram

Long-Term Outcome After Resection of Hepatic and Pulmonary Metastases in Multivisceral Colorectal Cancer

Comparison of percutaneous ablation and hepatectomy for liver metastasis: A single center retrospective study

Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors

Clinical Outcomes and Predictors in Patients with Unresectable Colorectal Cancer Liver Metastases Following Salvage Percutaneous Radiofrequency Ablation: A Single Center Preliminary Experience

The Current Application of Thermal Ablation in Colorectal Liver Metastasis.

Early Intrahepatic Recurrence of Hepatocellular Carcinoma after Hepatectomy Treated with Re-Hepatectomy, Ablation or Chemoembolization: a Prospective Cohort Study.

Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art